French Govt Has The Chance To Act Now To Boost Pharma Prospects, Says Industry Body
Sales growth is slowing, innovation is being impaired, and prices remain constrained in France, says the industry body Leem. It has called on the government to take urgent action to remedy the situation.
You may also be interested in...
The French pharmaceutical industry association is cautiously optimistic that the new government will take a longer-term view of the industry’s contribution to healthcare, and has proposed a pact setting out the relations between the industry and the state.
Two new quality guidelines are needed to address the increase in applications for clinical trials and marketing authorizations of oligonucleotide- and peptide-based medicines, says the EU regulator.
The European Commission has laid out a number of possibilities for changing the EU framework on compulsory licensing to improve the availability of products in health emergencies. The options include extending the scope of compulsory licences beyond patents to other forms of protection such as data exclusivity.